Nehal J Lakhani (Nehal Lakhani)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 17

Top Topics

Monoclonal Antibody

Advanced Non Small Cell Lung Cancer

Peripheral Blood

Top Venues

Journal for immunotherapy of cancer

Cancer research

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Omid Hamid, Karl D Lewis, Amy Weise, Meredith A McKean, Kyriakos P Papadopoulos, John Crown, Tae Min Kim, Dae Ho Lee, Sajeve S Thomas, Janice Mehnert, John Kaczmar, Nehal J Lakhani, Kevin B Kim, Mark Ross Middleton, Guilherme Rabinowits, Alexander I Spira, Melinda Yushak, Inderjit Mehmi, Fang Fang, Shuquan Chen, Jayakumar Mani, Vladimir Jankovic, Fang Wang, Nathalie Fiaschi, Laura Brennan, Anne J Paccaly, Sheila Masinde, Mark Salvati, Matthew G Fury, Glenn S Kroog, Israel Lowy, Giuseppe Gullo
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Ludimila Cavalcante, Sreenivasa Chandana, Nehal J Lakhani, Amanda Enstrom, Heidi LeBlanc, Joseph Schmalz, Krisztina Lengyel, Frank Schneider, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski, Diwakar Davar
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. Journal for immunotherapy of cancer 12 (8) (2024)
Patricia J Keller, Elizabeth J Adams, Rentian Wu, Alexandre Côté, Shilpi Arora, Nico Cantone, Rosana Meyer, Jennifer A Mertz, Victor Gehling, Jike Cui, Jacob I Stuckey, Avinash Khanna, Feng Zhao, Zehua Chen, Ziyang Yu, Richard T Cummings, Mohammed Taimi, Nehal J Lakhani, Drew W Rasco, Martin Gutierrez, Linda R Duska, Michael Devitt, Ronda Rippley, Julian R Levell, Jennifer Truong, Jing Wang, Kaiming Sun, Patrick Trojer
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers. Cancer research 84 (15) (2024)
Ludimila Cavalcante, Sreenivasa Chandana, Nehal J Lakhani, Amanda Enstrom, Heidi LeBlanc, Joseph Schmalz, Krisztina Lengyel, Frank Schneider, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski, Diwakar Davar
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. Journal for immunotherapy of cancer 12 (8) (2024)
Ludimila Cavalcante, Sreenivasa Chandana, Nehal J Lakhani, Amanda Enstrom, Heidi LeBlanc, Joseph Schmalz, Krisztina Lengyel, Frank Schneider, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski, Diwakar Davar
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. Journal for immunotherapy of cancer 12 (8) (2024)
Patricia J Keller, Elizabeth J Adams, Rentian Wu, Alexandre Côté, Shilpi Arora, Nico Cantone, Rosana Meyer, Jennifer A Mertz, Victor Gehling, Jike Cui, Jacob I Stuckey, Avinash Khanna, Feng Zhao, Zehua Chen, Ziyang Yu, Richard T Cummings, Mohammed Taimi, Nehal J Lakhani, Drew W Rasco, Martin Gutierrez, Linda R Duska, Michael Devitt, Ronda Rippley, Julian R Levell, Jennifer Truong, Jing Wang, Kaiming Sun, Patrick Trojer
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers. Cancer research 84 (15) (2024)
Patricia J Keller, Elizabeth J Adams, Rentian Wu, Alexandre Côté, Shilpi Arora, Nico Cantone, Rosana Meyer, Jennifer A Mertz, Victor Gehling, Jike Cui, Jacob I Stuckey, Avinash Khanna, Feng Zhao, Zehua Chen, Ziyang Yu, Richard T Cummings, Mohammed Taimi, Nehal J Lakhani, Drew W Rasco, Martin Gutierrez, Linda R Duska, Michael Devitt, Ronda Rippley, Julian R Levell, Jennifer Truong, Jing Wang, Kaiming Sun, Patrick Trojer
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers. Cancer research (2024)
Omid Hamid, Karl D Lewis, Amy Weise, Meredith A McKean, Kyriakos P Papadopoulos, John Crown, Tae Min Kim, Dae Ho Lee, Sajeve S Thomas, Janice Mehnert, John Kaczmar, Nehal J Lakhani, Kevin B Kim, Mark Ross Middleton, Guilherme Rabinowits, Alexander I Spira, Melinda Yushak, Inderjit Mehmi, Fang Fang, Shuquan Chen, Jayakumar Mani, Vladimir Jankovic, Fang Wang, Nathalie Fiaschi, Laura Brennan, Anne J Paccaly, Sheila Masinde, Mark Salvati, Matthew G Fury, Glenn S Kroog, Israel Lowy, Giuseppe Gullo
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (24) (2024)
Omid Hamid, Karl D Lewis, Amy Weise, Meredith A McKean, Kyriakos P Papadopoulos, John Crown, Tae Min Kim, Dae Ho Lee, Sajeve S Thomas, Janice Mehnert, John Kaczmar, Nehal J Lakhani, Kevin B Kim, Mark Ross Middleton, Guilherme Rabinowits, Alexander I Spira, Melinda Yushak, Inderjit Mehmi, Fang Fang, Shuquan Chen, Jayakumar Mani, Vladimir Jankovic, Fang Wang, Nathalie Fiaschi, Laura Brennan, Anne J Paccaly, Sheila Masinde, Mark Salvati, Matthew G Fury, Glenn S Kroog, Israel Lowy, Giuseppe Gullo
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (24) (2024)
Patricia J Keller, Elizabeth J Adams, Rentian Wu, Alexandre Côté, Shilpi Arora, Nico Cantone, Rosana Meyer, Jennifer A Mertz, Victor Gehling, Jike Cui, Jacob I Stuckey, Avinash Khanna, Feng Zhao, Zehua Chen, Ziyang Yu, Richard T Cummings, Mohammed Taimi, Nehal J Lakhani, Drew W Rasco, Martin Gutierrez, Linda R Duska, Michael Devitt, Ronda Rippley, Julian R Levell, Jennifer Truong, Jing Wang, Kaiming Sun, Patrick Trojer
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers. Cancer research 84 (15) (2024)
Diwakar Davar, Ludimila Cavalcante, Nehal J Lakhani, Justin C Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E Sanborn, Jaspreet S Grewal, Ajita Narayan, Amita Patnaik, Justin F Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for immunotherapy of cancer 12 (8) (2024)
Diwakar Davar, Ludimila Cavalcante, Nehal J Lakhani, Justin C Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E Sanborn, Jaspreet S Grewal, Ajita Narayan, Amita Patnaik, Justin F Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for immunotherapy of cancer 12 (8) (2024)
Omid Hamid, Karl D Lewis, Amy Weise, Meredith A McKean, Kyriakos P Papadopoulos, John Crown, Tae Min Kim, Dae Ho Lee, Sajeve S Thomas, Janice Mehnert, John Kaczmar, Nehal J Lakhani, Kevin B Kim, Mark Ross Middleton, Guilherme Rabinowits, Alexander I Spira, Melinda Yushak, Inderjit Mehmi, Fang Fang, Shuquan Chen, Jayakumar Mani, Vladimir Jankovic, Fang Wang, Nathalie Fiaschi, Laura Brennan, Anne J Paccaly, Sheila Masinde, Mark Salvati, Matthew G Fury, Glenn S Kroog, Israel Lowy, Giuseppe Gullo
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (24) (2024)
Diwakar Davar, Ludimila Cavalcante, Nehal J Lakhani, Justin C Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E Sanborn, Jaspreet S Grewal, Ajita Narayan, Amita Patnaik, Justin F Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for immunotherapy of cancer 12 (8) (2024)
Nehal J Lakhani, Howard Burris, Wilson H Miller, Mo Huang, Lin-Chi Chen, Lillian L Siu
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors. Investigational new drugs (2024)
Vivek Subbiah, Sant P Chawla, Anthony P Conley, Breelyn A Wilky, Anthony W Tolcher, Nehal J Lakhani, David Berz, Vasily Andrianov, William Crago, Monica Holcomb, Abrahim Hussain, Carson Veldstra, James Kalabus, Brianne O'Neill, Lane Senne, Emily Rowell, Analeah B Heidt, Katelyn M Willis, Brendan P Eckelman
Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Nehal J Lakhani, Drew W Rasco, Hengbang Wang, Lichuang Men, Eric Liang, Lei Tommy Fu, Mary C Collins, Ping Min, Yan Yin, Matthew S Davids, Dajun Yang, Yifan Zhai
First-in-Human Study with preclinical data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)